Noven delays NDA

NOVN said that an NDA for its transdermal methylphenidate to treat attention deficit hyperactivity disorder

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE